Memorial Sloan Kettering Cancer Center9d
New Targeted Therapy Strategies for Addressing Non-Small Cell Lung Cancer Metastatic Disease
Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...
Cure Today27d
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer. Ensacove (ensartinib) has been approved by the Food and Drug ...
Zacks Investment Research on MSN1d
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
Bristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab) for another ...
pharmaphorum6d
NICE backs first targeted therapy for ALK+ lung cancer
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...
Nature6y
Developing isogenic cell models with CRISPR: an EML4-ALK fusion NSCLC cell line
An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene and tested for its ...